口服选择性雌激素受体降解剂抗乳腺癌新药艾拉司群

Oral selective estrogen receptor depressant,the new anti-breast cancer drug elacestrant

选择性雌激素受体降解剂(selective estrogen receptor degrader,SERD)是雌激素受体(estrogen receptor,ER)阳性的晚期乳腺癌(breast cancer)内分泌治疗的常用药物。艾拉司群(elacestrant)是治疗晚期乳腺癌ER阳性,人表皮细胞生长因子受体(human epidermal growth factor receptor,HER)2阴性的新型口服SERD,疗效优于其他内分泌治疗,可显著改善患者中位无进展生存期,且对于ER基因α突变的乳腺癌患者有效。艾拉司群的上市将为ER阳性、HER2阴性的晚期乳腺癌患者提供更有效的治疗药物选择。

Selective estrogen receptor degrader(SERD)is commonly used in the endocrine therapy of estrogen receptor(ER)positive advanced breast cancer.Elacestrant is a novel oral SERD that is for the treatment of advanced breast cancer with ER-positive and human epidermal growth factor receptor(HER)2-negative.It is more effective than other endocrine therapies and can significantly improve the median progression free survival of patients,and is also effective for breast cancer patients with ER geneαmutations.The launch of elacestrant will provide a more effective treatment option for patients with ER-positive,HER2-negative advanced breast cancer.